Oral nicotinamide safe for renal transplant recipients

Oral nicotinamide safe for renal transplant recipients
(HealthDay)—For renal transplant recipients, oral nicotinamide seems safe and is associated with nonsignificant reductions in new non-melanoma skin cancers (NMSCs), according to a study published online April 8 in the British Journal of Dermatology.

Andrew C. Chen, M.B., B.S., from the University of Sydney at Royal Prince Alfred Hospital, and colleagues examined the safety and preliminary efficacy of oral nicotinamide for NMSC prevention in recipients. They enrolled patients at least 12 months post-renal transplant, with stable kidney function, and a history of two or more histologically-confirmed NMSCs in the previous 12 months. Twenty-two participants were randomized in a 1:1 ratio to receive six months of nicotinamide 500 mg or twice daily.

The researchers found that within six months, participants taking placebo developed an average of 4.2 new NMSCs, compared with 2.7 among patients taking nicotinamide (rate ratio, 0.65; 95 percent confidence interval, 0.3 to 1.6). One patient with 20 NMSCs highly influenced the rate in the . There was a nonsignificant, 16 percent reduction in actinic keratoses associated with nicotinamide (95 percent confidence interval, −7 to 34 percent). No significant differences were seen in adverse events, creatinine, or blood pressure.

"A phase 3 study is now warranted to assess the chemopreventive efficacy of nicotinamide in renal ," the authors write.


Explore further

Vitamin B3 derivative cuts risk of new skin cancers

More information: Abstract
Full Text (subscription or payment may be required)
Journal information: British Journal of Dermatology

Copyright © 2016 HealthDay. All rights reserved.

Citation: Oral nicotinamide safe for renal transplant recipients (2016, April 19) retrieved 24 May 2019 from https://medicalxpress.com/news/2016-04-oral-nicotinamide-safe-renal-transplant.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
1 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more